Aclarion (ACON) announced plans to expand Nociscan access across key markets in New York and New Jersey. The expansion plans build on previously established Nociscan sites with RadNet (RDNT) affiliates in both states and are driven by the increased availability of MR Spectroscopy and enhanced remote operations capabilities within RadNet to meet growing market demand for Nociscan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACON:
- Aclarion Inc trading halted, volatility trading pause
- Aclarion announces first commercial agreement with Scripps Health in San Diego
- Aclarion, Inc. Adjourns Special Meeting for More Votes
- Aclarion receives U.S. patent on expanded applications of MRS data processing
- Aclarion announces Northwestern Medicine as first CLARITY trial site